Nicole Longo Nicole is director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
Stakeholders raise concerns with proposed drastic changes to the pharmaceutical supply chain
By Nicole Longo | June 11, 2020
As we work to combat the current global pandemic, it is especially critical to maintain the stability of our global manufacturing supply chain. Unfortunately, recent policy proposals that would...
Read More
America’s global leadership in biopharmaceutical manufacturing
By Nicole Longo | June 4, 2020
Unfortunately, there are a lot of assertions floating around that tell a misleading story about pharmaceutical manufacturing, diminishing America’s leadership and suggesting our reliance on other...
Read More
It’s a good thing pharmaceutical manufacturing supply chains are spread out around the world
By Nicole Longo | May 21, 2020
The biopharmaceutical industry is committed to ensuring Americans and people around the world have access to the medicines they need. As a result, companies do everything they can to make sure...
Read More
Setting up a pharmaceutical manufacturing supply chain is a complex and lengthy process
By Nicole Longo | May 14, 2020
Did you know that biopharmaceutical manufacturers must begin setting up the manufacturing supply chain for a medicine years before that medicine is even approved for use by patients? That’s a fact...
Read More
PhRMA submits comments to CMS on policy changes for in-home care under Part B during COVID-19
By Nicole Longo | May 6, 2020
The COVID-19 pandemic has caused a number of disruptions in our health care system, one of which is the ability for seniors to access their infused or injected Part B medicines normally...
Read More
PhRMA submits comments on FDA’s proposed rule on drug importation
By Nicole Longo | March 10, 2020
Yesterday, PhRMA submitted comments in response to the Food and Drug Administration’s proposed rule, “Importation of Prescription Drugs.” As PhRMA President and CEO Stephen J. Ubl stated when the...
Read More
Three reasons the Administration should abandon its International Pricing Index proposal
By Nicole Longo | January 31, 2020
According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American...
Read More
Drug importation: An old idea that is still a bad idea
By Nicole Longo | January 28, 2020
2020 may have kicked off a new decade, but policymakers are stuck in the past, focusing on old, dangerous ideas like drug importation. For all the same reasons we’ve discussed before, drug...
Read More
New GAO report: Some hospitals participating in 340B may not be eligible for the program
By Nicole Longo | January 14, 2020
The Government Accountability Office (GAO) released a new report on 340B hospital eligibility compliance and made a number of alarming observations that underscore the need for more accountability...
Read More
New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines
By Nicole Longo | December 5, 2019
The House of Representatives has spent much of this fall focused on Speaker Pelosi’s drug pricing bill, H.R.3, but a recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
